NCT06798376Completed
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
The Comparison of Different Cycles of PD-1 Blockades Combined With Chemotherapy as Neoadjuvant Therapy for Patients With Advanced Gastric Cancer
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 409 (actual)
- First submitted
- 16 Jan 2025
- Start date
- 16 Jan 2025
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Chinese PLA General Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06798376
What you commit to
- Study type: Observational
- Participants enrolled: 409
- From 16 Jan 2025 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Distant metastases present prior to treatment;
- Concurrent diagnosis of other malignancies.
Other
- Incomplete or inaccessible clinical and pathological data;
- Postoperative pathology confirming non-gastric or non-gastroesophageal junction adenocarcinoma;
Who the study is looking for
- Non-bedridden patients aged 18-90 years;
- Histologically confirmed gastric or gastroesophageal junction adenocarcinoma by biopsy;
- Evaluated as resectable advanced gastric cancer via CT, MRI, or laparoscopic exploration;
- No prior anti-tumor treatments such as chemotherapy, radiotherapy, or immunotherapy;
- No history of other malignancies within the past 5 years;
- Received at least one cycle of PD-1 inhibitor combined with chemotherapy preoperatively, with no restrictions on the specific PD-1 inhibitor or chemotherapeutic agents;
- Underwent radical gastrectomy after neoadjuvant therapy;
- No severe underlying diseases.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.